FOXP2 and cancer: Aside from the downregulation in CCM patients [119], low levels of miR-181a-2-3p, which targets FOXP2, have been linked to a poorer prognosis in patients with glioblastoma, although the exact acting mechanism of FOXP2 in these malignant tumors remains unclear [158].